转移性激素敏感性前列腺癌与联合治疗结局:综述
本综述总结转移性激素敏感性前列腺癌当前及新兴管理策略的最新证据,包括治疗强化联合方案。国际3期随机临床试验显示,雄激素剥夺治疗联合雄激素受体通路抑制剂和/或多西他赛显著改善生存,三联治疗较雄激素剥夺治疗联合多西他赛改善总生存。作者认为符合化疗条件者应接受雄激素剥夺治疗联合雄激素受体通路抑制剂联合多西他赛。
要点
- 雄激素剥夺治疗是转移性激素敏感性前列腺癌的治疗骨干,但单用不足以持续控制疾病和长期生存。
- 加用雄激素受体通路抑制剂和/或多西他赛显著改善生存,三联治疗较雄激素剥夺治疗联合多西他赛改善总生存。
- 作者建议符合化疗条件者接受雄激素剥夺治疗联合雄激素受体通路抑制剂联合多西他赛,尤其高瘤量、高危或新发转移者。
核心结论
- 国际3期随机临床试验证据支持对转移性激素敏感性前列腺癌患者起始三联联合治疗以获得最佳总生存。
- 作者认为符合化疗条件的患者应接受雄激素剥夺治疗联合雄激素受体通路抑制剂联合多西他赛,尤其高瘤量、高危或新发转移性疾病者。
研究设计与样本
- 本综述总结转移性激素敏感性前列腺癌当前及新兴管理策略的最新证据,并提供将证据应用于临床实践的建议。
- 证据来自多项国际3期随机临床试验,包括ARASENS、PEACE-1和ENZAMET试验。
主要发现
- ARASENS试验(达罗他胺)总人群HR 0.68(95% CI 0.57-0.80);新发和复发患者HR分别为0.71(95% CI 0.59-0.85)和0.61(95% CI 0.35-1.05);高瘤量和低瘤量患者HR分别为0.69(95% CI 0.57-0.82)和0.72(95% CI 0.41-1.13);高危和低危患者HR分别为0.71(95% CI 0.58-0.86)和0.62(95% CI 0.42-0.90)。
- PEACE-1试验(醋酸阿比特龙+泼尼松)总人群(均为新发)HR 0.75(95% CI 0.59-0.95);高瘤量亚组HR 0.72(95% CI 0.55-0.95),低瘤量亚组数据不成熟。
- ENZAMET试验(恩扎卢胺)总人群HR 0.82(95% CI 0.63-1.06);新发和复发亚组HR分别为0.73(95% CI 0.55-0.99)和1.10(95% CI 0.65-1.86);高瘤量和低瘤量亚组HR分别为0.87(95% CI 0.66-1.17)和0.61(95% CI 0.33-1.10)。
- 联合方案总体耐受良好,不良反应取决于组成药物的特征。
关键数值与推荐
- ARASENS试验中,达罗他胺三联治疗较雄激素剥夺治疗联合多西他赛改善总生存,总人群HR 0.68(95% CI 0.57-0.80)。
- PEACE-1试验中,醋酸阿比特龙+泼尼松三联治疗总人群HR 0.75(95% CI 0.59-0.95;均为新发)。
- ENZAMET试验中,恩扎卢胺联合治疗总人群HR 0.82(95% CI 0.63-1.06)。
临床怎么用
- 作者认为符合化疗条件的患者应接受雄激素剥夺治疗联合雄激素受体通路抑制剂联合多西他赛,尤其高瘤量、高危或新发转移性疾病者。
- 三联联合治疗被作者推荐用于转移性激素敏感性前列腺癌患者以获得最佳总生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metastatic hormone-sensitive prostate cancer is currently an incurable disease. Despite a high response rate to androgen-deprivation therapy, most cases progress to castration-resistant disease, the terminal phase. This review provides a summary of the most recent evidence for current and emerging management strategies, including treatment intensification with combinations of therapies. It also provides recommendations on applying the evidence in clinical practice to encourage appropriate treatment to improve survival outcomes among patients with metastatic hormone-sensitive prostate cancer. OBSERVATIONS: Androgen-deprivation therapy is the backbone of treatment for metastatic hormone-sensitive prostate cancer; however, it is insufficient alone to provide sustained disease control and long-term survival. Addition of an androgen receptor pathway inhibitor and/or docetaxel significantly improves survival, as demonstrated by several international phase 3 randomized clinical trials. Triplet therapy composed of androgen-deprivation therapy plus an androgen receptor pathway inhibitor plus docetaxel has been shown to improve overall survival over androgen-deprivation therapy plus docetaxel. In the ARASENS trial (darolutamide), the hazard ratios (HRs) were 0.68 (95% CI, 0.57-0.80) in the overall population; 0.71 (95% CI, 0.59-0.85) and 0.61 (95% CI, 0.35-1.05) in patients with de novo and recurrent disease, respectively; 0.69 (95% CI, 0.57-0.82) and 0.72 (95% CI, 0.41-1.13) in patients with high-volume and low-volume disease, respectively; and 0.71 (95% CI, 0.58-0.86) and 0.62 (95% CI, 0.42-0.90) in patients with high-risk and low-risk disease, respectively. In the PEACE-1 trial (abiraterone acetate + prednisone), the HRs were 0.75 (95% CI, 0.59-0.95; all de novo) in the overall population and 0.72 (95% CI, 0.55-0.95) and immature in the high-volume and low-volume subgroups, respectively. In the ENZAMET trial (enzalutamide), the HRs were 0.82 (95% CI, 0.63-1.06) in the overall population; 0.73 (95% CI, 0.55-0.99) and 1.10 (95% CI, 0.65-1.86) in the de novo and recurrent subgroups, respectively; and 0.87 (95% CI, 0.66-1.17) and 0.61 (95% CI, 0.33-1.10) in the high-volume and low-volume subgroups. Combination regimens are generally well tolerated, with adverse effects dependent on the profiles of the component drugs. CONCLUSIONS AND RELEVANCE: The findings of this review show compelling evidence from phase 3 randomized clinical trials in favor of initiating triplet combination therapy for patients with metastatic hormone-sensitive prostate cancer for the best overall survival. Patients who are eligible for chemotherapy should be offered androgen-deprivation therapy plus an androgen receptor pathway inhibitor plus docetaxel, particularly patients with high-volume, high-risk, or de novo metastatic disease.
引用
- Hussain M, Fizazi K, Shore ND, et al. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. JAMA Oncol. 2024. PMID: 38722620. doi:10.1001/jamaoncol.2024.0591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。